Myriad Genetics
Article Abstract:
A comparative analysis of the company sales and financial details of Myriad Genetics, Inc. from 1996 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Neurocrine Biosciences Inc
Article Abstract:
Neurosciences Inc.'s operating cost this year will result in a sizable loss despite a rise in revenues due to an agreement with Pfizer for Indiplon, an insomnia product. Stock has speculative appeal and pr ice appreciation potential out to 2006-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Myriad Genetics
Article Abstract:
Myriad Genetics Inc. has spent on direct-to-consumer ads pushing the bottom line deeper into the red. Analysts are awaiting the ads' effectiveness and at this time there is no hurry into commitments for the stock.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: